COLLABORATIVE ARRANGEMENTS (Details Textual) - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	[1]	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Research and Development Expense, Total										$ 2,874	$ 2,678	$ 1,712
Revenues	$ 18,035	$ 19,972	$ 19,516	$ 18,799	$ 21,037		$ 17,387	$ 6,647	$ 10,899	76,322	55,970	30,082
Riconpharma LLC [Member]
Research and Development Expense, Total										31	400	700
Sofgen Pharmaceuticals [Member] | August 2013 Sofgen Agreement [Member]
Research and Development Expense, Total										400	200	$ 200
Revenues										7
Sofgen Pharmaceuticals [Member] | April 2014 Sofgen Agreement [Member]
Research and Development Expense, Total										$ 37	$ 100

[1] Net income from continuing operations, Basic income per share from continuing operations, and Diluted income per share from continuing operations for the fourth quarter of 2014 include the impact of an income tax benefit to reverse $16.7 million of the valuation allowance preiously recorded against our deferred tax assets.